Efficacy, Safety, and Pharmacokinetics of Golimumab in Children with Moderately-To-Severely Active Ulcerative Colitis: Results from the PURSUIT 2 Study
Inflammatory Bowel Diseases · 2026
DOI: 10.1093/ibd/izaf322 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Inflammatory Bowel Diseases, 2026. Verfasst von Dan Turner und 13 weiteren Autor:innen. Beteiligte Einrichtung: The Juliet Keidan Institute of Pediatric Gastroenterology and Nutrition, Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Jerusalem, …. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Antibodies, Monoclonal. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Johnson & Johnson.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Golimumab is an anti-TNFα biologic agent that has been approved for adults with moderately-to-severely active ulcerative colitis (UC). We investigated the efficacy, safety, and pharmacokinetics (PK) of golimumab in biologic-naïve children with moderately-to-severely active UC.
Methods
The prospective, multicenter, open-label PURSUIT 2 study enrolled biologic-naïve children (2 to <18 years) with moderately-to-severely active UC (Mayo score 6-12; endoscopic subscore ≥2) despite conventional treatment. During the 6-week induction phase, patients received subcutaneous (SC) golimumab dosed by weight (<45 kg: 120/60 mg/m2; ≥45 kg: 200/100 mg) at weeks 0/2. Week 6 clinical responders (Mayo score decrease from baseline ≥30% and ≥3 points, with either a decrease in the rectal bleeding subscore of ≥1 or a rectal bleeding subscore of 0/1) continued golimumab dose q4w during the 48-week maintenance phase. The primary endpoint was clinical remission (Mayo score ≤2 points with no individual subscore >1) at week 6. Efficacy and PK data are presented alongside a reference adult UC population who received golimumab SC 200/100 mg at weeks 0/2 and 100 mg q4w thereafter.
Results
Of the 69 patients (mean age, 13.4 ± 3.3 years) enrolled, 31.9% (22/69) were in clinical remission at week 6, and of those, 54.5% (12/22) remained in clinical remission at week 54. At week 54, 31.7% (13/41) of week 6 clinical responders achieved clinical remission. Additionally, 33.3% achieved clinical remission by the Pediatric Ulcerative Colitis Activity Index (PUCAI), 56.5% clinical response by Mayo, 40.6% endoscopic improvement, and 7.2% endoscopic remission at week 6. Of those who were clinical responders at week 6, 34.1% achieved clinical remission by PUCAI, 31.7% corticosteroid-free clinical remission by Mayo, 36.6% endoscopic improvement, and 9.8% endoscopic remission at week 54. Serum golimumab concentrations through week 6 were comparable to the reference adult UC population. Through week 54, 40.6% reported serious adverse events and 13.0% serious infections. No new safety concerns were identified.
Conclusions
Overall, the results of the PURSUIT 2 study support golimumab treatment for children with moderately-to-severely active UC. ClinicalTrials.gov ID: NCT03596645
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Juliet Keidan Institute of Pediatric Gastroenterology and Nutrition, Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Jerusalem, 91031, Israel.
- Johnson & Johnson, Spring House, PA, 19477, United States.
- Universitair Ziekenhuis, Vrije Universiteit Brussel, Brussels, 1090, Belgium.
- The Hospital for Sick Children, University of Toronto, Toronto, Ontario, ON M5G 1X8, Canada.
- The Children's Memorial Health Institute, Warsaw, 04-730, Poland.
- Kyungpook National University Chilgok Hospital, Daegu, 41944, South Korea.
ORCID-Profile: Dan Turner, Kathleen G Lomax, Anne M Griffiths, Ben Kang, Omoniyi J Adedokun, Jeffrey S Hyams
Förderung
- Johnson & Johnson
Zitieren
APA
Turner, D., Lomax, K. G., Veereman, G., Griffiths, A. M., Kierkuś, J., Kang, B., Berezny, K., Padgett, L., Mao, G., Zitser, Y., Strauss, R. S., Verhoeven, J., Adedokun, O. J., & Hyams, J. S. (2026). Efficacy, Safety, and Pharmacokinetics of Golimumab in Children with Moderately-To-Severely Active Ulcerative Colitis: Results from the PURSUIT 2 Study. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izaf322
Vancouver
Turner D, Lomax KG, Veereman G, Griffiths AM, Kierkuś J, Kang B, et al. Efficacy, Safety, and Pharmacokinetics of Golimumab in Children with Moderately-To-Severely Active Ulcerative Colitis: Results from the PURSUIT 2 Study. Inflammatory Bowel Diseases. 2026. doi:10.1093/ibd/izaf322
BibTeX
@article{Turner2026,
author = {Turner, Dan and Lomax, Kathleen G and Veereman, Gigi and Griffiths, Anne M and Kierkuś, Jaroslaw and Kang, Ben and Berezny, Katherine and Padgett, Lakshmi and Mao, Gary and Zitser, Yevgeny and Strauss, Richard S and Verhoeven, Jeroen and Adedokun, Omoniyi J and Hyams, Jeffrey S},
title = {Efficacy, Safety, and Pharmacokinetics of Golimumab in Children with Moderately-To-Severely Active Ulcerative Colitis: Results from the PURSUIT 2 Study},
journal = {Inflammatory Bowel Diseases},
year = {2026},
doi = {10.1093/ibd/izaf322}
}
EUVIMED